Top

Published in:

01-01-2013 | Letter to the Editor

Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score

Authors: Andrea Tendas, Fabio Sollazzo, Pasquale Niscola, Luca Cupelli, Maria Rita Mauroni, Antonella D’Apolito, Vittoria Pilozzi, Stella Cacciaraichi, Caterina Viggiani, Adriana Concetta Pignatelli, Ombretta Annibali, Andrea Mengarelli, Teresa Dentamaro, Paolo de Fabritiis, William Arcese, on behalf of Rome Transplant Network Quality of Life Working Party

Published in: Supportive Care in Cancer | Issue 1/2013

Excerpt

Dear editor, …

Burmeister H, Aebi S, Studer C et al (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141–147PubMedCrossRef

Tendas A, Sollazzo F, Niscola P et al (2012) Management of chemotherapy-induced nausea and vomiting in adult patients after haematopoietic stem cell transplantation: adherence to guidelines and costs analysis from the Quality of Life Working Party of the Rome Transplant Network (EBMT 2012 Abstract N1228). Bone Marrow Transplant 47:S459–S470. doi:10.1038/bmt.2012.39 CrossRef

Tendas A, Sollazzo F, Bruno A et al (2012) Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Support Care Cancer 20(5):891–892PubMedCrossRef

Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992PubMedCrossRef

Title: Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score
Authors: Andrea Tendas
Fabio Sollazzo
Pasquale Niscola
Luca Cupelli
Maria Rita Mauroni
Antonella D’Apolito
Vittoria Pilozzi
Stella Cacciaraichi
Caterina Viggiani
Adriana Concetta Pignatelli
Ombretta Annibali
Andrea Mengarelli
Teresa Dentamaro
Paolo de Fabritiis
William Arcese
on behalf of Rome Transplant Network Quality of Life Working Party
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 1/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1550-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Systematic review of agents for the management of gastrointestinal mucositis in cancer patients

Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer

Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL)

The multidimensional nature of the financial and economic burden of a cancer diagnosis on patients and their families: qualitative findings from a country with a mixed public–private healthcare system

The efficiency of the acupressure in prevention of the chemotherapy-induced nausea and vomiting

How does the Distress Thermometer compare to the Hospital Anxiety and Depression Scale for detecting possible cases of psychological morbidity among cancer survivors?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer